Form 8-K - Current report:
SEC Accession No. 0001104659-26-047335
Filing Date
2026-04-23
Accepted
2026-04-23 09:01:32
Documents
15
Period of Report
2026-04-22
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2611622d1_8k.htm   iXBRL 8-K 45645
2 EXHIBIT 2.1 tm2611622d1_ex2-1.htm EX-2.1 541220
3 EXHIBIT 10.1 tm2611622d1_ex10-1.htm EX-10.1 101578
4 EXHIBIT 99.1 tm2611622d1_ex99-1.htm EX-99.1 18170
8 GRAPHIC tm2611622d1_ex99-1img001.jpg GRAPHIC 25234
  Complete submission text file 0001104659-26-047335.txt   1060048

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA cpix-20260422.xsd EX-101.SCH 3038
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE cpix-20260422_lab.xml EX-101.LAB 34239
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE cpix-20260422_pre.xml EX-101.PRE 22374
18 EXTRACTED XBRL INSTANCE DOCUMENT tm2611622d1_8k_htm.xml XML 3102
Mailing Address 1600 WEST END AVENUE SUITE 1300 NASHVILLE TN 37203
Business Address 1600 WEST END AVENUE SUITE 1300 NASHVILLE, TN 37203 615-255-0068
CUMBERLAND PHARMACEUTICALS INC (Filer) CIK: 0001087294 (see all company filings)

EIN.: 621765329 | State of Incorp.: TN | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-33637 | Film No.: 26885830
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)